Valens Groworks (CSE: VGW) a Vancouver-based cannabis company with broad seed to sale and farm to pharma goals, announced it is entering a partnership with the worldwide scientific testing powerhouse Thermo Fisher Scientific to advance its capabilities to conduct scientific studies and trials.
Valens Groworks is a wholly owned subsidiary of Supra THC. The partnership is to create a “center of excellence in plant-based medicine analytics.” Supra has a 17,000 sq ft state-of-the-art facility in Kelowna that is under renovation. They will use Thermo Fisher’s instrumentation to provide analytical services, R&D, forensic analysis, and support for clinical trials.
Thermo Fisher is a US$20 billion company providing life sciences research and medicines. They have 65,000 employees worldwide.
Valens stock traded up 21% on the news to close at $1.14. It has a market cap of $68 million. Shares have traded between $0.490 – $1.650 over the last 52 weeks.
Source: Valens Groworks press release